Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 4.1  

 
 

AMENDMENT TO RIGHTS AGREEMENT    
  

        AMENDMENT TO RIGHTS AGREEMENT, dated as of March 19, 2002 (this "Amendment"), by and between Collateral Therapeutics, Inc., a Delaware corporation
(the "Company"), and American Stock Transfer & Trust Company, as Rights Agent (the "Rights Agent"). Capitalized terms used in this Amendment without definition shall have the respective
meanings given to them in the Rights Agreement, dated as of September 19, 2001 (the "Rights Agreement"), by and between the Company and the Rights Agent. 

        WHEREAS,
the Company and the Rights Agent have entered into the Rights Agreement; 

        WHEREAS,
pursuant to Section 27 of the Rights Agreement the Company has the power to amend the Rights Agreement; 

        WHEREAS,
in connection with the execution of the Agreement and Plan of Merger, dated as of the date of this Amendment, by and among Schering AG, a stock corporation organized under the
laws of the Federal Republic of Germany (the "Parent"), European Acquisition Company, a Delaware corporation and a wholly owned subsidiary of Parent (the "Sub"), and the Company, the board of
directors of the Company has approved and adopted this Amendment rendering the Rights Agreement inapplicable to the Merger Agreement (as defined below), the Stockholders Agreement (as defined below)
and the transactions contemplated by the Merger Agreement and the Stockholders Agreement. 

        NOW
THEREFORE, in consideration of the foregoing, the parties hereto, intending to be legally bound, hereby agree as follows: 

        Section 1.    Amendment of Section 1 of the Rights Agreement.    The definition of "Acquiring Person" in
Section 1 of the Rights Agreement is hereby amended by inserting the following clause (ii) and renumbering clauses (ii) and (iii) to clauses (iii) and (iv),
respectively: 

        (ii)  the
acquisition of Beneficial Ownership of shares of Common Stock of the Company by Schering AG, a stock corporation organized under the laws of the Federal Republic of
Germany (the "Parent"), or European Acquisition Company, a Delaware corporation and a wholly owned subsidiary of Schering ("Sub") by virtue of execution and delivery of, or the consummation of the
transactions contemplated by, the (A) Agreement and Plan of Merger, dated as of March 19, 2002 (the "Merger Agreement"), by and among the Parent, Sub and the Company, or (B) the
Stockholders Agreement, dated as of March 19, 2002 (the "Stockholders Agreement"), by and between the Parent and certain stockholders of the Company which was executed in connection with the
execution and delivery of the Merger Agreement, shall not, whether alone or together with the Beneficial Ownership of shares of Common Stock of the Company prior to the date of the Merger Agreement by
the Parent, its Affiliates or Associates, cause Parent, Sub or any of their Affiliates or Associates to become an "Acquiring Person" for any purpose of this Agreement. 

        Section 2.    Amendment of Section 7 of the Rights Agreement.    Section 7 of the Rights
Agreement is hereby amended by deleting paragraph (a) thereof in its entirety and inserting in lieu thereof the following: 

        (a)  The
registered holder of any Rights Certificate evidencing exercisable Rights may exercise the Rights evidenced thereby (except as otherwise provided in this Agreement)
in whole or in part at any time after the Distribution Date upon surrender of the Rights Certificate, with the form of election to purchase and the related certification duly executed, to the Rights
Agent at the office of the Rights Agent designated for such purpose, together with payment of the Purchase Price for each Rights being exercised (as such amount may be reduced (including to zero)
pursuant to Section 11(a)(iii)) and an amount equal to any applicable transfer tax required to be paid by the holder of such Rights Certificate 

1

 

in accordance with Section 9 in cash, or by certified check, wire transfer or bank draft payable to the order of the Company, at or prior to the earliest of (i) the Close of Business on
the tenth anniversary hereof (the "Final Expiration Date"), (ii) the time at which the Rights are redeemed as provided in Section 23 (the "Redemption Date"), (iii) the time at
which the Rights are exchanged as provided in Section 24 and (iv) immediately prior to the Effective Time (as defined in the Merger Agreement) (the earliest of (i), (ii),
(iii) and (iv) being the "Expiration Date"). 

        Section 3.    Amendment of Section 29 of the Rights Agreement.    Section 29 of the Rights
Agreement is amended by adding the following clause (c): 

        (c)  For
the avoidance of doubt, the board of directors of the Company has determined that no Distribution Date, Share Acquisition Date or Triggering Event shall occur solely
by virtue of the
execution or delivery of the Merger Agreement or the Stockholders Agreement or the consummation of the transactions contemplated thereby. 

        Section 4.    Miscellaneous; Section 27 Certification.    

        (a)  Except
as set forth in this Amendment, the Rights Agreement and the Rights remain in full force and effect and are unmodified. From and after the execution and delivery
of this Amendment, all references in the Rights Agreement to "this Agreement" shall refer to the Rights Agreement as amended by this Amendment. 

        (b)  If
any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect and shall in no way be affected, impaired or invalidated;  provided,
however, that notwithstanding anything in this Amendment to the contrary, if any such term,
provision, covenant or restriction is held by such court or authority to be invalid, void or unenforceable and the board of directors of the Company determines in its good faith judgment that severing
the invalid language from this Amendment would adversely affect the purpose or effect of this Amendment and the right of redemption set forth in Section 23 of the Rights Agreement shall have
expired, such right shall be reinstated and shall not expire until the tenth Business Day following the date of such determination by the board of directors of the Company. 

        (c)  This
Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with
the internal laws of the State of Delaware applicable to contracts to be made and performed entirely within such state, without regard to the choice-of-law or
conflict-of-laws principles of any jurisdiction. 

        (d)  This
Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute one and the same instrument. 

        (e)  Descriptive
headings of the several sections of this Amendment are inserted for convenience only and shall not control or affect the meaning or construction of any of
the provisions of this Amendment. 

        (f)    The
undersigned officer of the Company, being an appropriate officer of the Company and authorized to do so by resolution of the board of directors of the Company dated
as of March 19, 2002, hereby certifies to the Rights Agent that these amendments are in compliance with the terms of Section 27 of the Rights Agreement. 

2

 

        IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written. 

	 	 	COLLATERAL THERAPEUTICS, INC.
	

 	
 	

By:	
 	

/s/  CHRISTOPHER J. REINHARD      
	 	 	 	 	

	 	 	Name:	 	Christopher J. Reinhard
	 	 	Title:	 	President and Chief Operating Officer
	

 	
 	

AMERICAN STOCK TRANSFER & TRUST COMPANY
	

 	
 	

By:	
 	

/s/  HERBERT J. LEMMER      
	 	 	 	 	

	 	 	Name:	 	Herbert J. Lemmer
	 	 	Title:	 	Vice President

3

QuickLinks

AMENDMENT TO RIGHTS AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.24    
  

November
28, 2001 

Leonard
R. Stein

2218 Clay Street

San Francisco, California 94115 

Dear
Lenny, 

As
a result of our recent discussions, it is with pleasure that I confirm our offer for your employment with QRS Corporation. The following summarizes our offer: 

POSITION  

Senior
Vice President, General Counsel & Secretary. You will be a member of the Corporate Management Committee and will attend Board of Directors meetings. 

REPORTING TO  

Liz
Fetter, President & CEO 

LOCATION  

Richmond,
California 

START DATE  

November 30th,
2001 

ANNUAL COMPENSATION  

Your
annual compensation will be administered by me and reviewed by the Compensation Committee of the Board of Directors. Our agreement regarding compensation is as follows: 

          (i)  Your
annual base compensation will be $240,000 or $20,000 per month. QRS employees are paid semi-monthly (i.e., on the
fifteenth and last working day of each month). 

        (ii)   In
addition, you will receive annual incentive compensation of not less than 50% of base compensation for
fiscal year 2002 that will be administered by me and reviewed by the Compensation Committee. Your annual incentive compensation for fiscal year 2002 is guaranteed to be not less than $120,000. The sum
of your base compensation plus your annual incentive compensation shall be your total target
compensation. 

During
2001 your short-term incentive compensation will depend on your start date, but assuming November 30th, it would be approximately $10,000. 

Notwithstanding
the above, the annual total target compensation (base compensation plus incentive at 100%), shall not be less than $360,000 and for 2001
the total target compensation (base compensation plus incentive at 100%) will depend on your start date, but again assuming November 30th, it should approximate $30,000. 

        (iii)  You
will also receive a one-time payment of $10,000. 

Your
compensation, including incentives, will be reviewed in April 2002 and each year thereafter (unless there is a change in objectives, responsibilities etc., in which case it will be reviewed at
that time), to ensure that it continues to be equitable, appropriate to your responsibilities and provide appropriate incentives and support to the agreed objectives. 

REIMBURSEMENT  

QRS
will reimburse you for all business expenses reasonably incurred by you in the performance of your duties hereunder. You will adhere to QRS' travel and entertainment polices and procedures, submit
expense reports with appropriate vouchers, receipts, and other substantiation of such expenses within thirty (30) days after they are incurred and you should expect prompt reimbursement. 

QRS
will pay on your behalf your California and District of Columbia Bar fees, reasonable expenses to meet your continuing education requirements, and your memberships in the American Bar Association,
American Corporate Counsel Association and San Francisco Bar Association, including reasonable expenses of attending appropriate meetings of these organizations. 

LONG TERM INCENTIVES  

It
will be recommended that you receive the following stock option grants in accordance with the defined plan, copies of which are available for your review: 

        a.    Initial Grant.    Option to purchase 40,000 shares. This recommendation will be presented to the Board of
Directors for its approval on December 5, 2001. 

        b.    Deferred Initial Grant.    Option to purchase 25,000 shares. This grant shall occur as soon after your start
date as sufficient stock options become reasonably available under the plan, but shall occur not later than May 31, 2002. 

The
grant date for each stock option grant set forth above shall be the date the Board approves the grant, and the option price will be established by the closing price of the stock on that date. 

The
options set forth in (a) and (b) above will vest over a four-year period with 25% vesting beginning on the anniversary of the grant date and the remainder vesting in equal monthly increments
thereafter. If your employment terminates for any reason (whether or not in connection with a change in control of the Company), the options that have vested as of your termination date shall remain
exercisable for thirty six (36) months after the termination of your service with the Company or such longer period as the Plan or Plan Administrator may specify, provided that no option may be
exercised after the specified expiration date of the option term. 

BENEFITS  

In
addition to the benefits available to all QRS associates as defined in the Employee Handbook; as a Senior Vice President and Officer you are provided with additional benefits as follows: 

Disability
Insurance—The Company shall purchase and maintain in effect disability insurance sufficient to provide you with an income equal to 662/3% of your base
compensation while you are disabled and unable to perform the duties of your current employment with QRS. You will have the option of continuing this additional disability insurance coverage at your
own expense in the event of the termination of your employment. This additional insurance benefit is taxable and will be reported for tax purposes as additional income to you. 

Liability
Insurance—The Company shall purchase and maintain in effect sufficient Officer's liability insurance to provide you with reasonable coverage, including the provision of legal
counsel and/or reimbursement of appropriate legal fees you pay personally, against all liability claims and judgments arising from your legal exercise of your duties as an Officer of QRS, including
any actions filed after you cease your duties as an Officer or in the event of the termination of your employment. The Company shall also provide in its bylaws (and, upon reasonable request by you, in
a written
agreement), a full indemnification for you as a QRS officer, to the maximum extent permissible under Delaware law. 

Life
Insurance—The Company shall purchase and maintain in effect group term life insurance for you with a death benefit of equal to 2 times your base salary with beneficiary to be
designated by yourself. 

At your option, you may choose to purchase additional life insurance through the supplemental term life plan. 

PTO—You
will be entitled to 10 holidays per calendar year and 20 PTO (Personal Time Off) days per year. A prorated portion of PTO is accrued each pay period. PTO may be used for
vacation, illness or other purposes at your discretion. 

TERMINATION AND SEVERANCE  

This
position is for no set period or term and just as you have the right to resign your position, at any time, for any reason, QRS reserves the right to terminate your employment, at any time, with
or without cause, with or without notice. 

In
the event your employment is terminated without cause, you will become entitled to six (6) months of severance pay equal in the aggregate to your total annual target compensation and
benefits at the level in effect at the time of your termination. In addition, you shall be entitled to receive at the time of your termination the pro-rata amount (based upon the length of your
employment during the fiscal year) of your annual incentive compensation calculated at 100% of your target incentive. Your severance payments will be made in accordance with the Company's standard
payroll practices for current employees and will be subject to the Company's collection of all applicable withholding taxes. 

For
purposes of this agreement, termination "for cause" shall mean a termination of your employment for any of the following reasons: (1) your failure to substantially perform the material
duties of your position with the Company after a written demand for substantial performance is delivered to you by the Company which specifically identifies the manner in which you have not
substantially performed those duties and which provides a reasonable period for you to cure those deficiencies; (2) a material breach by you of your obligations under any confidential or
proprietary information agreements with the Company or of any of your fiduciary obligations as an officer of the Company, (3) your failure to follow in a material respect the reasonable
policies or directives established on an employee-wide basis by the Company, after written notice to you indicating the policies or directives with which you are not in material compliance and which
provides a reasonable period for you to cure those deficiencies,
(4) any willful misconduct on your part having a material detrimental effect on the Company or (5) any unauthorized activity on your part which creates a material conflict of interest
between you and the Company after you have been provided with written notice of the unauthorized activity and a reasonable opportunity to refrain from that activity. 

CHANGE OF CONTROL BENEFITS  

A.    Should
there occur a Corporate Transaction or a Change in Control (as those terms are defined in the Company's 1993 Stock Option/Stock Issuance Plan) and either (i) your
employment is subsequently terminated without cause or (ii) you subsequently resign by reason of a material change in your base compensation, your targeted annual incentive compensation, your
annual total target compensation, or your benefits (for this purpose, 15% will be deemed a material reduction), a material reduction in your duties or responsibilities, or a change in your principal
place of employment by more than 35 miles, then you will be entitled to six (6) months of severance pay equal in the aggregate to your targeted total annual target compensation and
benefits at the level in effect at the time of your termination or resignation or (if greater) at the level in effect immediately prior to the Corporate Transaction or Change in Control. In addition,
you shall be entitled to receive at the time of your termination the pro-rata amount (based upon the length of your employment during the fiscal year) of your annual incentive compensation calculated
at 100% of your target incentive. Your severance payments will be made in accordance with the Company's standard payroll practices for current employees and will be subject to the Company's collection
of all applicable withholding taxes. 

B.    Except
to the extent otherwise provided in paragraph C below, should a Corporate Transaction or Change in Control occur during your period of employment with the Company, then
(i) all of your outstanding options will, immediately prior to the specified effective date for the Corporate Transaction 

or Change in Control, become exercisable for all the shares at the time subject to those options, whether or not those options are to be assumed or replaced with a cash incentive program, and those
accelerated options may be exercised for all or any portion of the option shares as fully vested shares; and (ii) all of your unvested shares of QRS stock will immediately vest at the time of
such Corporate Transaction or Change in Control. 

C.    However,
the following limitation will be in effect for (i) all of your unvested shares of QRS stock and (ii) any unvested options which are to be assumed by the
successor entity (or parent company) or otherwise continued in effect or which are to be replaced with a cash incentive program which preserves the spread existing at the time of such Corporate
Transaction or Change in Control on any shares for which your options are not otherwise at that time exercisable (the excess of the fair market value of those shares over the exercise price): 

The
accelerated vesting of those unvested shares and options will be limited to the extent and only to the extent necessary to assure that the parachute payment attributable to the accelerated vesting
of those shares and options would not constitute an excess parachute payment under Internal Revenue Code Section 280G(b). 

To
the extent one of more of your options or unvested shares do not vest on an accelerated basis upon a Corporate Transaction or Change in Control by reason of such limitation, those options will
continue to become exercisable in accordance with the original exercise schedule indicated in the respective grant notices for those options, and those unvested shares will continue to vest in
accordance with the original vesting schedule set forth in the applicable Restricted Stock Agreements. However, should either (i) your employment be terminated without cause or (ii) you
resign by reason of a material change in your base compensation, your targeted annual incentive compensation, your annual total target compensation, or your benefits (for this purpose, 15% will be
deemed a material reduction), a material reduction in your duties or responsibilities, or a change in your principal place of employment by more than 50 miles, at the time of such Corporate
Transaction or Change in Control or within twenty four (24) months thereafter, then each of your outstanding options, to the extent not otherwise fully exercisable at that time, shall
automatically accelerate and become immediately exercisable for all the option shares and may be exercised for any or all of those shares as fully vested shares at any time prior to the expiration or
sooner termination of the option term. In addition, all of your unvested shares will immediately vest upon such a termination of employment or resignation. 

D.    Any
of your options which are assumed by the successor entity (or parent company) in the Corporate Transaction or are otherwise continue in effect following the Change in Control
transaction shall be appropriately adjusted to apply and pertain to the number and class of securities which would have been issued to you in the consummation of such Corporate Transaction or Change
in Control had the options been exercised immediately prior to such event. Appropriate adjustments shall also be made to the option prices payable per share, provided the aggregate option prices
payable shall remain the same. 

EMPLOYMENT AT WILL  

Your
employment in the position of General Counsel will remain an Employment At Will. This means that your position is for no set period or term and just as you have the right to resign your position,
at any time, for any reason, QRS reserves the right to terminate your employment, at any time, with or without cause and with or without notice. If any contrary representation has been made to you,
this letter supersedes it. Neither subsequent agreement contrary to this nor any amendment to this term can be made unless it is in writing and signed by both of us and copied to the Chairman of the
Compensation Committee. 

I
trust the above meets your approval. However, should you have any questions or concerns, you should not hesitate to contact either me. For our part we look forward, with tremendous enthusiasm, to
you joining QRS and our ongoing relationship. 

Sincerely,

	/s/  LIZ FETTER      
 Liz Fetter

CEO and President	 	 

c.c:
Garth Saloner—Chairman of the Compensation Committee 

I
accept this ongoing position with QRS Corporation on these terms and conditions on the terms above and understand and agree that it supersedes any other agreement, written or oral, I may have with
QRS with respect to employment or compensation by QRS including salary, incentive, options, termination and severance. 

	/s/  LEONARD R. STEIN      
 Leonard R. Stein	 	 

QuickLinks

Exhibit 10.24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]